查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球线粒体肌病治疗市场（2022-2029）
市场调查报告书
商品编码
1078249

全球线粒体肌病治疗市场（2022-2029）

Global Mitochondrial Myopathies Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告调查全球线粒体肌病治疗市场，包括市场概况、市场规模和预测、趋势、增长因素和挑战、客户情况、类型/测试类型/药物类型/治疗类型/分布。我们提供渠道分析/地区，以及公司简介。

目录

第1章调查方法及范围

  • 调查方法
  • 调查的目的和范围

第2章市场定义和概述

第 3 章执行摘要

  • 按类型划分的市场细分
  • 按检查类型划分的市场细分
  • 按药物类型划分的市场细分
  • 按治疗类型划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第4章市场动态

  • 影响市场的因素
    • 促进因素
    • 抑制器
    • 市场机会
    • 影响分析

第5章行业分析

  • 供应链分析
  • 价格分析
  • 未满足的需求

第 6 章 COVID-19 分析

  • 分析 COVID-19 对市场的影响
    • 之前的 COVID-19 市场情景
    • 当前 COVID-19 市场情况
    • COVID-19 后或未来情景
  • COVID-19 的价格波动
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略计划
  • 结论

第 7 章按类型

  • 简介
    • 按类型和同比增长分析的市场规模分析
    • 按类型划分的市场吸引力指数
  • Kearns-Sayer 综合征
    • 简介
    • 市场规模分析（2020-2029 和 2021-2029）
  • 线粒体 DNA 耗竭综合征 (MDS)
  • 线粒体脑肌病、乳酸性酸中毒和中风样发作 (MELAS)
  • 孕产妇耳聋和糖尿病 (MIDD)
  • 线粒体神经胃肠道脑肌病 (MNGIE)
  • 肌阵挛性癫痫伴破旧的红纤维 (MERRF)
  • 神经病变、共济失调和色素性视网膜炎 (NARP)
  • 皮尔逊综合征
  • 其他

第 8 章按检查类型

  • 简介
    • 按检查类型和同比增长分析的市场规模分析
    • 按检查类型划分的市场吸引力指数
  • 基因检测
    • 简介
    • 市场规模分析（2020-2029 和 2021-2029）
  • 肌肉活检
  • 血□检测
  • 其他检查

第 9 章按药物类型

  • 简介
    • 药物类型市场规模分析及同比增长分析
    • 按药物类型划分的市场吸引力指数
  • 辅□Q10
    • 简介
    • 市场规模分析（2020-2029 和 2021-2029）
  • 左旋肉碱
  • 肌酸
  • 其他

第 10 章按治疗类型

  • 简介
    • 按治疗类型和同比增长分析的市场规模分析
    • 按治疗类型划分的市场吸引力指数
  • 维生素
    • 简介
    • 市场规模分析（2020-2029 和 2021-2029）
  • 抗氧化
  • 支持性和靶向治疗
  • 其他

第 11 章按分销渠道

  • 简介
    • 分销渠道市场规模分析和同比增长分析
    • 按分销渠道划分的市场吸引力指数
  • 医院药房
    • 简介
    • 市场规模分析（2020-2029 和 2021-2029）
  • 零售药店
  • 网上药店
  • 其他

第 12 章按地区

  • 简介
    • 区域市场规模分析（2020-2029 年和 2021-2029 年）
    • 各地区市场吸引力指数
  • 北美
    • 简介
    • 特定地区的主要动态
    • 按类型和同比增长分析的市场规模分析
    • 按检查类型和同比增长分析的市场规模分析
    • 药物类型市场规模分析及同比增长分析
    • 按治疗类型和同比增长分析的市场规模分析
    • 分销渠道市场规模分析和同比增长分析
    • 特定国家市场规模分析和同比增长分析
  • 欧洲
    • 简介
    • 特定地区的主要动态
    • 按类型和同比增长分析的市场规模分析
    • 按检查类型和同比增长分析的市场规模分析
    • 药物类型市场规模分析及同比增长分析
    • 按治疗类型和同比增长分析的市场规模分析
    • 分销渠道市场规模分析和同比增长分析
    • 特定国家市场规模分析和同比增长分析
  • 南美洲
    • 简介
    • 特定地区的主要动态
    • 按类型和同比增长分析的市场规模分析
    • 按检查类型和同比增长分析的市场规模分析
    • 药物类型市场规模分析及同比增长分析
    • 按治疗类型和同比增长分析的市场规模分析
    • 分销渠道市场规模分析和同比增长分析
    • 特定国家市场规模分析和同比增长分析
  • 亚太地区
    • 简介
    • 特定地区的主要动态
    • 按类型和同比增长分析的市场规模分析
    • 按检查类型和同比增长分析的市场规模分析
    • 药物类型市场规模分析及同比增长分析
    • 按治疗类型和同比增长分析的市场规模分析
    • 分销渠道市场规模分析和同比增长分析
    • 特定国家市场规模分析和同比增长分析
  • 中东和非洲
    • 简介
    • 特定地区的主要动态
    • 按类型和同比增长分析的市场规模分析
    • 按检查类型和同比增长分析的市场规模分析
    • 药物类型市场规模分析及同比增长分析
    • 按治疗类型和同比增长分析的市场规模分析
    • 分销渠道市场规模分析和同比增长分析

第13章竞争态势

  • 主要发展及战略
  • 企业份额分析
  • 产品基准
  • 知名大公司名单

第 14 章公司简介

  • Pfanstiehl, Inc.
    • 公司简介
    • 产品组合/类型
    • 主要亮点
    • 财务概览
  • Ajinomoto Co., Inc.
  • BOTAY BIO-CHEM CO., LIMITED
  • Xi'an ZB Biotech Co., Ltd.
  • Kaneka Corporation
  • Lonza
  • AdvaCare Pharma
  • NutraBio Labs, Inc.

第 15 章全球线粒体肌病治疗市场：DataM

  • 附录
  • 关于我们公司/应用
  • 联繫我们
简介目录
Product Code: DMPH5158

Market Overview

The global mitochondrial myopathies treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Mitochondrial disorders are inherited chronic conditions marked by a variety of biochemical and genetic mitochondrial abnormalities and mutations. The condition affects the brain, heart, liver, skeletal muscles, kidneys, and respiratory systems, among other organs. Patients with mitochondrial disorders frequently experience muscle weakness, exercise intolerance, and weariness as a result of a reduction in mitochondrial respiration caused by mitochondrial DNA abnormalities that result in a decreased ability to synthesize cellular adenosine triphosphate (ATP). The majority of vitamins, co-factors, off-label medications approved for other reasons, and nutritional supplements are used to treat mitochondrial problems.

Market Dynamics

Innovative therapies in the clinical trials for the treatment of Mitochondrial Myopathies are expected to drive market growth.

Mitochondrial illnesses are genetically based, neither metabolic pathways nor symptomatic treatments can fundamentally fix them. Gene therapy is therefore the best option. Most advances in mitochondrial disease gene therapy have so far been focused on LHON. Pathogenic mutations of the mtDNA encoding complex IV subunit 4 are seen in about 70% of people with LHON (MT-ND4). The adeno-associated virus (AAV) can transport mtDNA, and its capsid VP2 can fuse with a plasmid targeting sequence to reexpress ND4. The expression of wild-type ND4 in ND4 mutant cells can help to correct ATP production problems. Moreover, This is the first time gene-editing technology has been used to change mtDNA in vivo, indicating that gene-editing technologies are utilized to treat mitochondrial illnesses.

Furthermore, research has shown considerable promise and is predicted to result in more effective treatment techniques for mitochondrial illnesses. Mitochondrial biogenesis enhancers (bezafibrate, epicatechin, and RTA 408), antioxidants (RP 103 and EPI-743), and cardiolipin protectors are among the medications now being studied (elamipretide). Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Higher R&D costs, more stringent drug approval restrictions, and a lack of knowledge and understanding of the condition are some of the factors expected to hamper the market growth in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 is extremely contagious in older people with weakened immune systems, and the risk of death rises with age and the presence of comorbidities including hypertension, diabetes, cardiovascular disease, or chronic obstructive pulmonary disease. There are several theories regarding mitochondria and their functions in inflammation that could explain why SARS-CoV-2 is wreaking havoc on the older population, particularly those with comorbidities. As a result, the importance of mitochondria in treatment development has increased. Over-stimulated or sustained inflammatory responses with interferon and cytokine production, regulation of fission and fusion, mitochondrial biogenesis, and interference with apoptosis and mitophagy are all possible linkages between aging mitochondria and reduced immunity. From bacteria to parasites to viruses like SARS-CoV-2, many pathogens have shown a predisposition to disrupt mitochondria as a strategy to influence host behavior once inside a cell by changing their processes.

Additionally, the pandemic interrupts the supply chain and clinical trials process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Others segment is expected to hold the largest market share in mitochondrial myopathies treatment market

The others segment is expected to dominate in 2021. The segment is bifurcated into Mito Cocktail, Exercise, and Mitochondrial Replacement Therapy (MRT). Moreover, there is no cure for mitochondrial abnormalities, there are several treatments that might help relieve symptoms. Treatments differ from person to person and are dependent on the type of mitochondrial dysfunction that has been detected. The Mito Cocktail consists of a combination of vitamin supplements such as acetyl-L-carnitine (ALCAR), coenzyme Q10 (CoQ10), and alpha-lipoic acid (ALA), and creatine monohydrate, which is the most common form of treatment (CM). It is a scientifically based mix of vitamins, cofactors, and nutrients that are known to replace deficits that develop when the mitochondrial energy production system fails and to improve the residual function of the mitochondrial energy production system.

Additionally, One of the most useful medicines is exercise, which has been clinically verified (as long as the patient can tolerate it). On a biological level, exercise boosts energy production, which enhances mitochondrial function and increases the number of healthy mitochondria in the cells. According to studies, exercise improves exercise tolerance and metabolism by allowing the body to use oxygen more efficiently. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global mitochondrial myopathies treatment market

In 2021, North America accounted for the highest revenue share. With the increasing prevalence of Mitochondrial Myopathies, rising demand for mitochondrial-based therapeutics, advancements in diagnostic facilities, and rising number of clinical trials to develop effective drugs for the disease along with the rise in several FDA approvals for novel drugs and therapies in the region are some of the factors the market is expected to boost in the forecast period. For instance, Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) are one of the most common mitochondrial diseases, with an estimated incidence of 1 in 4000, and mitochondria are carried out in the tails of sperm cells and hence discharged outside the zygote during fertilization, only women may pass the disease on to their children.

Moreover, The North American Mitochondrial Disease Consortium (NAMDC), which is part of the Rare Disease Clinical Research Network (RDCRN), collects information from mitochondrial disease patients in a clinical patient registry, which aids researchers in finding and recruiting participants for future studies. Additionally, The US Food and Drug Administration granted orphan therapeutic status to Reneo Pharmaceutical's main drug candidate REN001, to treat primary mitochondrial myopathy in June 2020. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the mitochondrial myopathies treatment market are Pfanstiehl, Inc., Ajinomoto Co., Inc., BOTAY BIO-CHEM CO., LIMITED, Xi'an ZB Biotech Co., Ltd., Kaneka Corporation, Lonza, AdvaCare Pharma and NutraBio Labs, Inc.

Lonza Group:

Overview:

Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology, and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America, and South Asia. The company provides product development services to the pharmaceutical and biologics industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

Product Portfolio:

Carnipure: Carnipure L-Carnitine is the nutrient needed to help support conversion of fat into metabolic energy. It provides benefits ranging from increasing blood flow, reducing markers of metabolic stress, decreasing muscle soreness and improving recovery time.

Why Purchase the Report?

  • Visualize the composition of the mitochondrial myopathies treatment market segmentation by type, test type, drug type, treatment type, distribution channel and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in mitochondrial myopathies treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of mitochondrial myopathies treatment market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global mitochondrial myopathies treatment market report would provide an access to an approx. 45+ market data table, 40+ figures and 200 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Test Type
  • 3.3. Market Snippet by Drug Type
  • 3.4. Market Snippet by Treatment Type
  • 3.5. Market Snippet by Distribution Channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovative therapies in the clinical trials for the treatment of Mitochondrial Myopathies are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Higher R&D costs is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Kearns-Sayre Syndrome*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Mitochondrial DNA depletion syndrome (MDS)
  • 7.4. Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
  • 7.5. Maternally inherited deafness and diabetes (MIDD)
  • 7.6. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
  • 7.7. Myoclonus epilepsy with ragged red fibers (MERRF)
  • 7.8. Neuropathy, ataxia, and retinitis pigmentosa (NARP)
  • 7.9. Pearson syndrome
  • 7.10. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type Segment
  • 8.2. Genetic Test*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Muscle biopsy
  • 8.4. Blood enzyme test
  • 8.5. Other tests

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type Segment
  • 9.2. CoQ10*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. L-carnitine
  • 9.4. Creatine
  • 9.5. Others

10. By Treatment Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 10.2. Vitamins*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Anti-oxidants
  • 10.4. Supportive and Targeted Therapy
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacy*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacy
  • 11.4. Online Pharmacy
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Pfanstiehl, Inc.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Ajinomoto Co., Inc.
  • 14.3. BOTAY BIO-CHEM CO., LIMITED
  • 14.4. Xi'an ZB Biotech Co., Ltd.
  • 14.5. Kaneka Corporation
  • 14.6. Lonza
  • 14.7. AdvaCare Pharma
  • 14.8. NutraBio Labs, Inc.

LIST NOT EXHAUSTIVE

15. Global Mitochondrial Myopathies Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us